These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37523890)

  • 41. Baseline severity of depression predicts antidepressant drug response relative to escitalopram.
    Kilts CD; Wade AG; Andersen HF; Schlaepfer TE
    Expert Opin Pharmacother; 2009 Apr; 10(6):927-36. PubMed ID: 19317630
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) Study.
    Kim HK; Zai G; Müller DJ; Husain MI; Lam RW; Frey BN; Soares CN; Parikh SV; Milev R; Foster JA; Turecki G; Farzan F; Mulsant BH; Kennedy SH; Tripathy SJ; Kloiber S
    Pharmacopsychiatry; 2022 Nov; 55(6):297-303. PubMed ID: 35793696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder.
    Saghafi R; Brown C; Butters MA; Cyranowski J; Dew MA; Frank E; Gildengers A; Karp JF; Lenze EJ; Lotrich F; Martire L; Mazumdar S; Miller MD; Mulsant BH; Weber E; Whyte E; Morse J; Stack J; Houck PR; Bensasi S; Reynolds CF
    Int J Geriatr Psychiatry; 2007 Nov; 22(11):1141-6. PubMed ID: 17486678
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
    Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
    J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine.
    Sun Y; Drevets W; Turecki G; Li QS
    Brain Behav Immun; 2020 Jul; 87():404-412. PubMed ID: 31978524
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Binding potential changes of SERT in patients with depression are associated with remission: A prospective [¹²³I]β-CIT-SPECT study.
    Krause D; Chrobok A; Karch S; Keeser D; Manz KM; Koch W; Brendel M; Rominger A; Koller G; Behle N; Pogarell O
    Exp Clin Psychopharmacol; 2023 Feb; 31(1):219-227. PubMed ID: 35604719
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial.
    Corruble E; de Bodinat C; Belaïdi C; Goodwin GM;
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2219-34. PubMed ID: 23823799
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study.
    Kadam RL; Sontakke SD; Tiple P; Motghare VM; Bajait CS; Kalikar MV
    Indian J Pharmacol; 2020; 52(2):79-85. PubMed ID: 32565594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.
    Lam RW; Milev R; Rotzinger S; Andreazza AC; Blier P; Brenner C; Daskalakis ZJ; Dharsee M; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Geraci J; Giacobbe P; Feilotter HE; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; Liotti M; MacQueen GM; McAndrews MP; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Salomons TV; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Kennedy SH;
    BMC Psychiatry; 2016 Apr; 16():105. PubMed ID: 27084692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patient Response Trajectories in Major Depressive Disorder.
    Larsen KG; Kennedy SH; Reines EH; Thase ME
    Psychopharmacol Bull; 2020 Sep; 50(4):8-28. PubMed ID: 33012870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1.
    Nunez JJ; Nguyen TT; Zhou Y; Cao B; Ng RT; Chen J; Frey BN; Milev R; Müller DJ; Rotzinger S; Soares CN; Uher R; Kennedy SH; Lam RW
    PLoS One; 2021; 16(6):e0253023. PubMed ID: 34181661
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
    Kennedy SH; Lam RW; Rotzinger S; Milev RV; Blier P; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Giacobbe P; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; McInerney S; MacQueen GM; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Sassi RB; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Yu J; Uher R;
    J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30840787
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
    Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
    Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predicting escitalopram monotherapy response in depression: The role of anterior cingulate cortex.
    Tian S; Sun Y; Shao J; Zhang S; Mo Z; Liu X; Wang Q; Wang L; Zhao P; Chattun MR; Yao Z; Si T; Lu Q
    Hum Brain Mapp; 2020 Apr; 41(5):1249-1260. PubMed ID: 31758634
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
    Bobo WV; Chen H; Trivedi MH; Stewart JW; Nierenberg AA; Fava M; Kurian BT; Warden D; Morris DW; Luther JF; Husain MM; Cook IA; Lesser IM; Kornstein SG; Wisniewski SR; Rush AJ; Shelton RC
    J Affect Disord; 2011 Oct; 133(3):467-76. PubMed ID: 21601287
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum amyloid P component level is associated with clinical response to escitalopram treatment in patients with major depressive disorder.
    Yang J; Zhou J; Zhou J; Wang H; Sun Z; Zhu X; He Y; Wong AHC; Liu F; Wang G
    J Psychiatr Res; 2022 Feb; 146():172-178. PubMed ID: 34995992
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased global integration in the brain after psilocybin therapy for depression.
    Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R
    Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.